Related Experiment Videos
Prostacyclin and heparin during haemodialysis: comparative effects
Life Support Systems : the Journal of the European Society for Artificial Organs
|July 1, 1986
Summary
Prostacyclin improves hemodialysis by reducing platelet issues and neutropenia. Combining prostacyclin with low-dose heparin enhances ultrafiltration volume, improving dialysis efficiency and biocompatibility.
Area of Science:
- Nephrology
- Pharmacology
Background:
- Hemodialysis can cause complications like neutropenia and platelet activation.
- Prostacyclin (epoprostenol sodium salt) is a potent vasodilator and inhibitor of platelet aggregation.
Purpose of the Study:
- To evaluate the effects of prostacyclin, alone and with heparin, on hemodialysis parameters.
- To assess improvements in biocompatibility and efficiency during hemodialysis.
Main Methods:
- Three dialysis regimens were compared in ten patients: heparin alone, prostacyclin alone, and prostacyclin with heparin.
- Measurements included platelet count, platelet aggregation, beta-thromboglobulin levels, neutropenia, membrane sieving coefficient, and ultrafiltration volume.
Main Results:
- Prostacyclin infusion decreased platelet count, aggregation, and beta-thromboglobulin, and improved hemodialysis neutropenia.
- Prostacyclin alone did not improve membrane sieving or ultrafiltration.
- Prostacyclin with low-dose heparin significantly improved ultrafiltration volume compared to heparin alone.
Conclusions:
- Prostacyclin effectively mitigates adverse platelet effects and neutropenia during hemodialysis.
- Combination therapy with prostacyclin and low-dose heparin enhances hemodialysis efficiency and biocompatibility.